The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up

Autor: D. Shaw, Kenneth Bridges, D. Gardner, A. Platt, A. Brenner, S. Valdez, F. Danny Armstrong, J. Chow, Brian Adler, Margaret Telfer, S. Gargiulo, D. Peace, R. O'Brien, Wendell F. Rosse, Maureen Okam, D. Davies, A. Davis, S. Claster, V. Knors, P. Ryans, D. Temple, L. White, Timothy M. Carlos, Susan B. Shurin, R. Harrell, Y. Barber, K. Williams, K. Chiarucci, E. Case, Elliott Vichinsky, Charles H. Pegelow, N. Lewis, P. Gascon, J. Siteman, Carolyn Bigelow, B. Tynan, A. Palmer, T. Saunders, P. Di Paolo, Rita Bellevue, K. Genther, B. Schmidt, W. Labrousse, O. C. Onyekwere, G. Pendarvis, C. Hoehner, D. Strayhorn, A. Anderson, M. McGee, Nancy F. Olivieri, A. Tracy, Yogen Saunthararajah, Wally R. Smith, Kenneth I. Ataga, J. Braddock, Brian W. Berman, Ward Hagar, Stephen H. Embury, Elyse Mandell, Lisa Daitch, M. Hui, V. Sabahi, A. Johnson-Telfair, Myron A. Waclawiw, Samir K. Ballas, A. Roundtree-Schmotzer, T. McArdle, L. Waller, L. Eskridge, B. Maddox, M. Bryan, L. Usry, N. Talischy-Zahed, Paul F. Milner, J. H. Bailey, Abdullah Kutlar, Elliott Perlin, Josef T. Prchal, M. Sheikhai, E. M. Rodriguez, Oswaldo Castro, E. Hackney-Stevens, L. Dorn, G. E. Allen, L. Keverline, S. Hernandez, K. McLaughlin, A. Earles, Harvey Dosik, Martin H. Steinberg, E. Carter-Randall, Helga Finke, J. Moshang, Laura DeCastro, T. Harrington, E. Wilkes, C. Winograd, H. Souffrant, S. Childerie, G. Ramirez, Eugene P. Orringer, William F. McCarthy, B. Scott, Paul Swerdlow, Mabel Koshy, James R. Eckman, K. Kleman, George Phillips, C. Nwokolo, Susan Jones
Rok vydání: 2010
Předmět:
Zdroj: American Journal of Hematology.
ISSN: 1096-8652
0361-8609
Popis: A randomized, controlled clinical trial established the efficacy and safety of short-term use of hydroxyurea in adult sickle cell anemia. To examine the risks and benefits of long-term hydroxyurea usage, patients in this trial were followed for 17.5 years during which they could start or stop hydroxyurea. The purpose of this follow-up was to search for adverse outcomes and estimate mortality. For each outcome and for mortality, exact 95% confidence intervals were calculated, or tests were conducted at alpha = 0.05 level (P-value
Databáze: OpenAIRE